Q2 EPS Estimates for Elevance Health Boosted by Analyst

Elevance Health, Inc. (NYSE:ELV) – Research analysts at Zacks Research boosted their Q2 2025 earnings estimates for Elevance Health in a research report issued on Wednesday, December 18th. Zacks Research analyst K. Dey now expects that the company will post earnings per share of $10.35 for the quarter, up from their previous estimate of $10.22. The consensus estimate for Elevance Health’s current full-year earnings is $32.96 per share. Zacks Research also issued estimates for Elevance Health’s Q4 2025 earnings at $4.68 EPS, Q2 2026 earnings at $11.90 EPS, Q3 2026 earnings at $10.65 EPS and FY2026 earnings at $40.48 EPS.

Elevance Health (NYSE:ELV) last posted its earnings results on Thursday, October 17th. The company reported $8.37 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $9.66 by ($1.29). The firm had revenue of $44.72 billion during the quarter, compared to the consensus estimate of $43.47 billion. Elevance Health had a net margin of 3.68% and a return on equity of 19.56%. The business’s revenue was up 5.3% on a year-over-year basis. During the same quarter last year, the firm posted $8.99 EPS.

A number of other equities research analysts have also recently commented on ELV. StockNews.com cut Elevance Health from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. Royal Bank of Canada cut their price target on shares of Elevance Health from $585.00 to $478.00 and set an “outperform” rating on the stock in a research report on Friday, October 18th. Cantor Fitzgerald decreased their price objective on shares of Elevance Health from $600.00 to $485.00 and set an “overweight” rating for the company in a report on Friday, October 18th. Barclays lowered their target price on shares of Elevance Health from $622.00 to $501.00 and set an “overweight” rating for the company in a research note on Tuesday, October 22nd. Finally, Stephens reissued an “underperform” rating on shares of Elevance Health in a report on Friday, October 18th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $539.20.

Elevance Health Price Performance

Elevance Health stock opened at $365.96 on Monday. The business’s 50-day simple moving average is $409.70 and its 200 day simple moving average is $488.69. The company has a quick ratio of 1.50, a current ratio of 1.50 and a debt-to-equity ratio of 0.56. The stock has a market cap of $84.87 billion, a price-to-earnings ratio of 13.34, a P/E/G ratio of 1.15 and a beta of 0.83. Elevance Health has a 12-month low of $362.21 and a 12-month high of $567.26.

Elevance Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, December 20th. Shareholders of record on Thursday, December 5th were given a dividend of $1.63 per share. The ex-dividend date was Thursday, December 5th. This represents a $6.52 dividend on an annualized basis and a yield of 1.78%. Elevance Health’s dividend payout ratio (DPR) is 23.77%.

Insider Buying and Selling at Elevance Health

In related news, EVP Charles Morgan Kendrick, Jr. sold 7,417 shares of the stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $432.14, for a total transaction of $3,205,182.38. Following the sale, the executive vice president now owns 8,423 shares of the company’s stock, valued at $3,639,915.22. This represents a 46.82 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 0.35% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Cambridge Investment Research Advisors Inc. lifted its stake in shares of Elevance Health by 16.4% in the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 32,467 shares of the company’s stock valued at $17,592,000 after acquiring an additional 4,566 shares during the last quarter. Atomi Financial Group Inc. grew its holdings in Elevance Health by 7.9% during the 2nd quarter. Atomi Financial Group Inc. now owns 590 shares of the company’s stock worth $320,000 after acquiring an additional 43 shares during the last quarter. AustralianSuper Pty Ltd increased its position in Elevance Health by 14.8% in the 2nd quarter. AustralianSuper Pty Ltd now owns 7,898 shares of the company’s stock valued at $4,280,000 after acquiring an additional 1,016 shares during the period. Patriot Financial Group Insurance Agency LLC lifted its holdings in shares of Elevance Health by 12.8% during the second quarter. Patriot Financial Group Insurance Agency LLC now owns 4,012 shares of the company’s stock worth $2,174,000 after purchasing an additional 456 shares during the period. Finally, LS Investment Advisors LLC grew its stake in shares of Elevance Health by 19.3% in the second quarter. LS Investment Advisors LLC now owns 5,774 shares of the company’s stock worth $3,129,000 after purchasing an additional 933 shares during the last quarter. 89.24% of the stock is owned by institutional investors.

Elevance Health Company Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.